Sitagliptin ameliorates diabetic nephropathy by blocking TGF-β1/Smad signaling pathway

Diabetic nephropathy (DN) is the leading cause of end-stage failure of the kidney, but the efficacy of current strategies available for the prevention of DN remains unsatisfactory. The purpose of this study was to assess whether sitagliptin (SIT) has therapeutic potential for prevention of DN and to...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Int J Mol Med
Hoofdauteurs: Wang, Dongdong, Zhang, Guanying, Chen, Xiao, Wei, Tong, Liu, Chenxu, Chen, Chun, Gong, Yinhan, Wei, Qunli
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: D.A. Spandidos 2018
Onderwerpen:
Articles
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5846674/
https://ncbi.nlm.nih.gov/pubmed/29484381
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ijmm.2018.3504
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items